Triple-negative breast cancers (TNBCs) are a heterogenous subgroup characterized by their lack of expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). TNBC is unique in that its lack of receptor expression often portends a poorer prognosis and poses unique therapeutic challenges. The variation in its gene expression has created a dynamic tumor microenvironment, which is often associated with chemoresistance, aggressive behavior, and frequent recurrence [3,4]. Here, ESR1 is linked to triple-negative breast carcinoma.